Home > Newsletters > Devices & Diagnostics Letter > Innovation Pathway Advances May Be Expanded Throughout Agency
Devices & Diagnostics Letter
May 7, 2012 | Vol. 39 No. 19
Innovation Pathway Advances May Be Expanded Throughout Agency
CINCINNATI — Regulatory advances made during the Innovation Pathway 2.0 project to develop new treatments for end-stage renal disease may quickly be rolled throughout CDRH, center Director Jeffrey Shuren said Wednesday at the FDA/Xavier University MedCon Conference here.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.